NOVEL IMMUNOTHERAPIES (CAR-T, BiTE)

This retrospective cohort study of 137 patients who had received CAR T-cell therapy for either lymphoma (88%) or myeloma (8%) demonstrated that cytokine release syndrome (CRS) occurred in 59% of patients. Of the 39% of patients with grade 2 or higher CRS, 54% experienced elevated troponin and 28% decreased left ventricular ejection fraction.